This is the authors' abstract. We don't add key points for this paper.
The burgeoning field of targeted protein degradation has witnessed significant advancements with the development of proteolysis‐targeting chimeras (PROTACs). This mini‐review aims to provide an insightful overview of the latest advancements in cancer therapy, particularly the evolution of stimuli‐responsive, controlled, self‐assembled PROTACs. We explore a spectrum of innovative developments, including photo‐responsive PROTACs, near‐infrared‐activated PROTACs, and those that functions based on biorthogonal reactions. The emergence of polymer‐based PROTACs is also highlighted, underscoring their improved efficacy and specificity. Despite their potential, these novel approaches face significant challenges, particularly in clinical translation. This review underscores the achievements of these ground‐breaking technologies and the hurdles that must be overcome to realize their full therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Sapkota et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: